PECS Block: Plasma Bupivacaine Level

• Status: Completed
• Trial end date: 2017-11-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine peak plasma bupivacaine concentrations in a similar fashion for PECS I/II blocks. The investigators hypothesis is that the mean peak plasma levels for patients undergoing PECS I/II blocks will be less than the levels reported to cause early neurotoxicity of [2.2 (0.9) micrograms/ml]6 in patients receiving intravenous bupivacaine infusions.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• Patients receiving a unilateral PECS I and II block for any surgery being provided by Wake Forest Baptist Medical Center

Exclusion Criteria:

• Subjects with contraindications to regional anesthesia, such as a history of allergy to amide local anesthetics,

• presence of a progressive neurological deficit,

• a pre-existing coagulopathy,

• infection at site of injection.

• or the following conditions:

• patient receiving any other additional local anesthetic from another procedure

• infection over site of block

• patient refusal

• significant renal or liver dysfunction on laboratory analysis

• weight <60 kg

• pregnancy